177 related articles for article (PubMed ID: 23134386)
21. Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate.
Cancer Discov; 2016 Feb; 6(2):OF3. PubMed ID: 26701087
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Van den Mooter T; Teuwen LA; Rutten A; Dirix L
Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
[TBL] [Abstract][Full Text] [Related]
24. HER2 testing in patients with breast cancer.
Dixon JM; Wilson V; Verrill M; Symmans WF
BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
[No Abstract] [Full Text] [Related]
25. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
26. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.
Singh JC; Lichtman SM
Drugs Aging; 2015 Dec; 32(12):975-82. PubMed ID: 26645293
[TBL] [Abstract][Full Text] [Related]
27. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
28. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).
Chung YC; Kuo JF; Wei WC; Chang KJ; Chao WT
PLoS One; 2015; 10(7):e0133072. PubMed ID: 26172389
[TBL] [Abstract][Full Text] [Related]
29. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
31. T-DM1 aids patients with advanced breast cancer.
Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
[No Abstract] [Full Text] [Related]
32. Update on antibody-drug conjugates in breast cancer.
Hugo HS
Clin Adv Hematol Oncol; 2021 Mar; 19(3):148-151. PubMed ID: 33739962
[No Abstract] [Full Text] [Related]
33. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.
Weiler D; Diebold J; Strobel K; Aebi S; Gautschi O
J Thorac Oncol; 2015 Apr; 10(4):e16-7. PubMed ID: 25789838
[No Abstract] [Full Text] [Related]
34. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
Doroshow DB; LoRusso PM
Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
[TBL] [Abstract][Full Text] [Related]
35. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
36. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?
Esteva FJ; Miller KD; Teicher BA
Am Soc Clin Oncol Educ Book; 2015; ():e117-25. PubMed ID: 25993162
[TBL] [Abstract][Full Text] [Related]
37. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
38. [Antibody-drug conjugate--a new age for personalized cancer treatment].
Bertholjotti I
Chimia (Aarau); 2011; 65(9):746-8. PubMed ID: 22026193
[No Abstract] [Full Text] [Related]
39. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
40. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
Elsada A; Doss S; Robertson J; Adam EJ
Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
